Format

Send to

Choose Destination
Cancer Sci. 2015 Oct;106(10):1402-7. doi: 10.1111/cas.12740. Epub 2015 Aug 18.

Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancer.

Author information

1
Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
2
Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
3
Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan.
4
Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.
5
Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
6
Department of Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan.
7
Department of Pathology, National Cancer Center Hospital, Tokyo, Japan.

Abstract

The frequency and clinical profile of patients with stage III non-small cell lung cancer harboring KRAS mutations have not yet been well documented. Here, we analyzed hotspot KRAS mutations using high-resolution melting analyses in tumor specimens from patients who received chemoradiotherapy between January 2001 and December 2010 at the National Cancer Center Hospital. The associations between the presence of KRAS mutations and the response rate, relapse-free survival, first relapse sites, survival post-progression and overall survival were investigated. A total of 274 non-squamous non-small cell lung cancer patients received chemoradiotherapy at our hospital. After excluding 121 patients for whom tumor specimens were not available and 34 patients with EGFR mutations, the remaining 119 patients were included in the analysis. KRAS mutations were found at a frequency of 13%. Patients with KRAS mutations had a shorter median relapse-free survival (6.1 vs 10.9 months) and a lower response rate (63% vs 81%). As for the first relapse site, patients with KRAS mutations had fewer local relapses (8% vs 23%) and more brain metastases (46% vs 12%). After disease progression, patients with KRAS mutations had a significantly shorter median survival post-progression (2.5 vs 7.3 months, P = 0.028) and median overall survival (15.1 vs 29.1 months, P = 0.022). Our results suggested that KRAS mutation could be associated with a reduced efficacy of chemoradiotherapy and a shortened survival time.

KEYWORDS:

Biomarkers; KRAS; chemoradiotherapy; non-small cell lung cancer; relapse

PMID:
26177347
PMCID:
PMC4637997
DOI:
10.1111/cas.12740
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center